Navigation Links
MAQUET Cardiovascular Launches HEARTSTRING III Proximal Seal System for Coronary Artery Bypass Graft Surgery
Date:4/14/2008

Innovative technology eliminates the need for an aortic clamp reducing the risk for cerebral emboli and potentially improving patient neurocognitive

outcomes

SAN JOSE, Calif., April 14 /PRNewswire/ -- MAQUET Cardiovascular LLC today announced the launch of HEARTSTRING III Proximal Seal System for coronary artery bypass surgery procedures. This latest version of MAQUET's innovative HEARTSTRING proximal seal technology allows surgeons to perform coronary artery bypass grafts without the use of a partial occlusion clamp during beating heart surgery.

"We firmly believe that off-pump beating heart surgery results in better patient outcomes. The HEARTSTRING device provides a means to reduce aortic manipulation, a well-appreciated risk factor for adverse neurologic complications in coronary artery bypass," said John D. Puskas M.D., Chief of Cardiac Surgery at Emory Crawford Long Hospital and Professor of Surgery. "With its unique features and improved delivery system, the new HEARTSTRING III system makes it easier for the cardiac surgeon to perform a clampless proximal anastomosis for either saphenous vein or radial artery conduits."

The HEARTSTRING III system features an improved seal loader and delivery device for fast, easy placement. Once deployed, it maintains a low compliant profile for optimal hemostasis at the anastomotic site. The HEARTSTRING III system enables surgeons to use their own hand-suturing technique for creating a proximal anastomosis with either venous or arterial grafts. With its elegant design and small operational footprint, there is no foreign material left inside the vessel after completion of the anastomosis. The Aortic Cutter makes a single, clean hole in the aorta for graft placement. The HEARTSTRING III system allows for maximum surgical flexibility. Surgeons have the option to perform distal or proximal grafts first and to use grafts of varying lengths, hooded grafts, and angled ta
'/>"/>

SOURCE MAQUET Cardiovascular LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
2. ARJO / Getinge / Maquet Announces New West Coast Showroom Opening
3. Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
4. Sexual dissatisfaction in postmenopausal women not linked to cardiovascular disease
5. Mary Cheney Joins the Cheney Cardiovascular Institute Board of Directors
6. 2-drug blood pressure therapy lowers cardiovascular risk
7. Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women
8. Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors
9. Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACCs 57th Annual Scientific Session
10. Medical Simulation Corporation to Present Comprehensive Cardiac Patient Scenario at the Society for Cardiovascular Angiography and Interventions (SCAI) and American College of Cardiology (ACC) Conference
11. Study finds certain liver disease related to cardiovascular fitness

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... more letters from the North Pole, Textsanta.net l... from Santa , North Pole,...l efficiencies at the North Pole Santa Claus has a...over the globe informed of his Christmas progress ...arch department have identified a large and growin...
(Date:11/26/2009)...search Triangle Dental (RTDental), a leading denta...announced the expansion of its services to include...ug Macmillan. , Durham...d to announce that Dr. Doug Macmillan, an experien...itional advanced training seminar. RTDental&rsquo...
(Date:11/26/2009)...nis & Ennis, P.A. is offering free nationwide ...smin birth control pills who have suffered a Deep ... Heart Attack or other related cardiac issues or h...free at 1-800-856-6405 or go to the firm’s w...n online case evaluation form. , ...
(Date:11/25/2009)...5/PRNewswire/--TheBartleHallConventionCenterwillte...c.9-10,whenKansasCityhoststhelatestinaseriesofmass...liniceventhasthepotentialtobethebiggestoneyet,beca...donweekdaysinsteadofoveraweekend,"SheriWood,execut...dentoftheNationalAssociationofFreeClinics(NAFC). ,...
(Date:11/25/2009)...v.25/PRNewswire/-SentinelleMedicalInc.,aleadingman...ftwareandCalgaryScientificInc.,aleadingproviderofs...ionofAegis(TM)Breast4DAdvancedVisualizationsoftwar...o-footprintWebclientbasedmedicalimagingofferingint...owsforzero-footprintaccess-requiringnosoftwaredown...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...army to find clues that may help to build therapie... Dr. Lynn Boyd, an associate professor of biology ...o find out what effect certain enzymes will have, ...y at Redstone Arsenal. While it is not known...
...y may have the potential to reverse impairments in...a first-of-its-kind study published in the Journal... the study was rich in flavanols, naturally-occurr...ucts. These results suggest this flavanol-rich...
...s the breakdown of a brain system that regulates a...a possible target for new drug therapies to help i... of American adults are overweight and around 30 p... The research provides new understanding of ...
... make people even more wary of using agricultural ... a common chemical weed killer could be the hidden...sease, at least those with certain genes that rend...from the University of Alabama,conducted an experi...
...al health conditions are potentially around the co... study. The findings, which were based on anal...d cells, appear online March 6 in the American Jou...t, M.D., Ph.D., professor of psychiatry in the UI ...
...mitted suicide in Assam in the last few months whi.../ as there is virtually no access to treatment. ...le who committed suicide in recent months. The sit...ent of the Assam Network of Positive People (ANPP)...
Other Medicine News:Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 3Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 4Health News:Targeting SOCS-3 can Control Obesity 2Health News:Weed Killer Plays a Pivotal Role in Those With Genetic Vulnerability to Parkinson’ 2Health News:Blood Tests may Be Possible for Mental Health Conditions 2Health News:Assam Reports HIV Suicides, Treatment a Distant Dream 2
(Date:11/25/2009)...Newswire/--Reportlinker.comannouncesthatanewmarket...itedStatesDentalDevicesMarketAnalysisandForecastst.../United-States-Dental-Devices-Market-Analysis-and-...vicesMarketAnalysisandForecaststo2015 ,, Summa...informationanddatarelatingtotheUSdentaldevicesmark...
(Date:11/25/2009)...RNewswire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA )...orminimallydisruptivesurgicaltreatmentsforthespine...ay,November30,2009,at5:30p.m.ET/2:30p.m.PT.Theconf...rsementfortheCompany,sproductsandwillincludecommen...ession.Thedial-innumbersare1-877-407-4018fordomest...
(Date:11/25/2009)...ndSYDNEY,Nov.25/PRNewswire-FirstCall/--HeartWareIn...novatorandprovideroflessinvasive,miniaturizedcircu...ntofadvancedheartfailure,todayannouncedthatitissch...iperJaffrayHealthCareConferenceat8:00amESTonWednes...wYorkPalaceHotel,December1-2. ,, Alivewebcastof...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference 60960 1Pharma and Biotech Leaders to Converge in Shanghai 14765 1Pharma and Biotech Leaders to Converge in Shanghai 14765 2AMD LASERS Names Dr James Jesse as Medical Director 6091 1AMD LASERS Names Dr James Jesse as Medical Director 6091 2
...III study will evaluate effects of otelixizumab, a...n preservation of endogenous insulin ...il 9, 2008 /PRNewswire/ - Tolerx, Inc., a,biopharm...elopment of novel,therapies for immune-mediated di...rd the initiation of a Phase III study of otelixiz...
...LANTA, April 9, 2008 Dutch biotechnology,company ...on and the South,African Tuberculosis Vaccine Init...ology data from a Phase I Ad35 tuberculosis vaccin... the World" conference (Atlanta,Georgia, April 9 t...uth,Africa and launched in May 2007, is the second...
Other Medicine Technology:Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 2Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 3Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 2Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 3Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 5Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 6
... is variably N-glycosylated. The variation account...tween 43 and 56 kDa. Insulin-like growth factor bi...inity but do not bind insulin. Of the six distinct...t this time, IGFBP-3 has been shown to be the majo...
...00 tests per year through automatic scheduling and...rocessing up to 4 assays on 4 plates simultaneousl... presentation of the results, are controlled by Wi...ube rack) and 256 (POS-ID Linear Rack) samples can...
Immunosimplicity® Is-ENA Screen Test Kit
IMMULITE 2000 IGFBP-3
Medicine Products: